Updated: Aug 18, 2009
Nystagmus may be defined as a periodic rhythmic ocular oscillation of the eyes. The oscillations may be sinusoidal and of approximately equal amplitude and velocity (pendular nystagmus) or, more commonly, with a slow initiating phase and a fast corrective phase (jerk nystagmus).1
Nystagmus may be unilateral or bilateral, but, when the nystagmus appears unilateral, it is more often asymmetric rather than truly unilateral. Nystagmus may be conjugate or disconjugate (dissociated). It may be horizontal, vertical, torsional (rotary), or any combination of these movements superimposed upon each other.
Nystagmus may be congenital or acquired. When acquired, it most often is caused by abnormalities of vestibular input. Congenital forms may be associated with afferent visual pathway abnormalities (sensory nystagmus).2
To understand the mechanisms by which nystagmus may occur, it is important to discuss the means by which the nervous system maintains position of the eyes. Foveal centration of an object of regard is necessary to obtain the highest level of visual acuity. Three mechanisms are involved in maintaining foveal centration of an object of interest: fixation, the vestibulo-ocular reflex, and the neural integrator.
Fixation in the primary position involves the visual system's ability to detect drift of a foveating image and signal an appropriate corrective eye movement to refoveate the image of regard. The vestibular system is intimately and complexly involved with the oculomotor system.
The vestibulo-ocular reflex is a complex system of neural interconnections that maintains foveation of an object during changes in head position. The proprioceptors of the vestibular system are the semicircular canals of the inner ear. Three semicircular canals are present on each side, anterior, posterior, and horizontal. The semicircular canals respond to changes in angular acceleration due to head rotation.
The third mechanism is the neural integrator. When the eye is turned in an extreme position in the orbit, the fascia and ligaments that suspend the eye exert an elastic force to return toward the primary position. To overcome this force, a tonic contraction of the extraocular muscles is required. A gaze-holding network called the neural integrator generates the signal. The cerebellum, ascending vestibular pathways, and oculomotor nuclei are important components of the neural integrator.
A disorder affecting any of the 3 mechanisms that control eye movements may result in nystagmus. Both focal and diffuse disorders may cause nystagmus. The characteristics of the nystagmus, as well as associated signs and symptoms help to localize the lesion and suggest possible etiologies.
Vestibular nystagmus
Vestibular nystagmus may be central or peripheral. Important differentiating features between central and peripheral nystagmus include the following: peripheral nystagmus is unidirectional with the fast phase opposite the lesion; central nystagmus may be unidirectional or bidirectional; purely vertical or torsional nystagmus suggests a central location; central vestibular nystagmus is not dampened or inhibited by visual fixation; tinnitus or deafness often is present in peripheral vestibular nystagmus, but it usually is absent in central vestibular nystagmus. According to Alexander's law, the nystagmus associated with peripheral lesions becomes more pronounced with gaze toward the side of the fast-beating component; with central nystagmus, the direction of the fast component is directed toward the side of gaze (eg, left-beating in left gaze, right-beating in right gaze, up-beating in upgaze).
Downbeat nystagmus
Downbeat nystagmus is defined as nystagmus with the fast phase beating in a downward direction.3 The nystagmus usually is of maximal intensity when the eyes are deviated temporally and slightly inferiorly. With the eyes in this position, the nystagmus is directed obliquely downward. In most patients, removal of fixation (eg, by Frenzel goggles) does not influence slow phase velocity to a considerable extent; however, the frequency of saccades may diminish.
The presence of downbeat nystagmus is highly suggestive of disorders of the craniocervical junction (eg, Arnold-Chiari malformation). This condition also may occur with bilateral lesions of the cerebellar flocculus and bilateral lesions of the medial longitudinal fasciculus, which carries optokinetic input from the posterior semicircular canals to the third nerve nuclei. It may also occur when the tone within pathways from the anterior semicircular canals is relatively higher than the tone within the posterior semicircular canals. Under such circumstances, the relatively unopposed neural activity from the anterior semicircular canals causes a slow upward pursuit movement of the eyes with a fast, corrective downward saccade.
Upbeat nystagmus
Upbeat nystagmus is defined as nystagmus with the fast phase beating in an upward direction. Daroff and Troost described 2 distinct types.4 The first type consists of a large amplitude nystagmus that increases in intensity with upward gaze. This type is suggestive of a lesion of the anterior vermis of the cerebellum. The second type consists of a small amplitude nystagmus that decreases in intensity with upward gaze and increases in intensity with downward gaze. This type is suggestive of lesions of the medulla.5
This condition may occur when the tone within the pathways of the posterior semicircular canals is relatively higher than the tone within the anterior semicircular canals, and it can occur from lesions of the ventral tegmental tract or the brachium conjunctivum, which carry optokinetic input from the anterior semicircular canals to the third nerve nuclei.
Torsional (rotary) nystagmus
Torsional (rotary) nystagmus refers to a rotary movement of the globe about its anteroposterior axis. Torsional nystagmus is accentuated on lateral gaze. Most nystagmus resulting from dysfunction of the vestibular system has a torsional component superimposed on a horizontal or vertical nystagmus.
This condition occurs with lesions of the anterior and posterior semicircular canals on the same side (eg, lateral medullary syndrome). Lesions of the lateral medulla may produce a torsional nystagmus with the fast phase directed away from the side of the lesion. This type of nystagmus can be accentuated by otolithic stimulation by placing the patient on their side with the intact side down (eg, if the lesion is on the left, the nystagmus is accentuated when the patient is placed on his right side).
Pendular nystagmus
Pendular nystagmus is a multivectorial nystagmus (ie, horizontal, vertical, circular, elliptical) with an equal velocity in each direction that may reflect brain stem or cerebellar dysfunction. Often, there is marked asymmetry and dissociation between the eyes. The amplitude of the nystagmus may vary in different positions of gaze.6
Horizontal nystagmus
Horizontal nystagmus is a well-recognized finding in patients with a unilateral disease of the cerebral hemispheres, especially with large, posterior lesions. It often is of low amplitude. Such patients show a constant velocity drift of the eyes toward the intact hemisphere with fast saccade directed toward the side of the lesion.
Seesaw nystagmus
Seesaw nystagmus is a pendular oscillation that consists of elevation and intorsion of one eye and depression and extorsion of the fellow eye that alternates every half cycle. This striking and unusual form of nystagmus may be seen in patients with chiasmal lesions, suggesting loss of the crossed visual inputs from the decussating fibers of the optic nerve at the level of the chiasm as the cause or lesions in the rostral midbrain. This type of nystagmus is not affected by otolithic stimulation.
Gaze-evoked nystagmus
Gaze-evoked nystagmus is produced by the attempted maintenance of an extreme eye position. It is the most common form of nystagmus. Gaze-evoked nystagmus is due to a deficient eye position signal in the neural integrator network. Thus, the eyes cannot be maintained at an eccentric orbital position and are pulled back toward primary position by the elastic forces of the orbital fascia. Then, corrective saccade moves the eyes back toward the eccentric position in the orbit.7
Gaze-evoked nystagmus may be caused by structural lesions that involve the neural integrator network, which is dispersed between the vestibulocerebellum, the medulla (region of the nucleus prepositus hypoglossi and adjacent medial vestibular nucleus [NPH/MVN]), and the interstitial nucleus of Cajal (INC). Patients recovering from a gaze palsy go through a period where they are able to gaze in the direction of the previous palsy, but they are unable to sustain gaze in that direction; therefore, the eyes drift slowly back toward primary position followed by a corrective saccade. When this is repeated, a gaze-evoked or gaze-paretic nystagmus results.
Gaze-evoked nystagmus often is encountered in healthy patients; in which case, it is called end-point nystagmus. End-point nystagmus usually can be differentiated from gaze-evoked nystagmus caused by disease, in that the former has lower intensity and, more importantly, is not associated with other ocular motor abnormalities.
Spasmus nutans
Spasmus nutans is a rare condition with the clinical triad of nystagmus, head nodding, and torticollis. Onset is from age 3-15 months with disappearance by 3 or 4 years. Rarely, it may be present to age 5-6 years. The nystagmus typically consists of small-amplitude, high frequency oscillations and usually is bilateral, but it can be monocular, asymmetric, and variable in different positions of gaze.
Periodic alternating nystagmus
Periodic alternating nystagmus is a conjugate, horizontal jerk nystagmus with the fast phase beating in one direction for a period of approximately 1-2 minutes. The nystagmus has an intervening neutral phase lasting 10-20 seconds; the nystagmus begins to beat in the opposite direction for 1-2 minutes; then, the process repeats itself. The presumed mechanism is disruption of the vestibulo-ocular tracts at the pontomedullary junction.8
Abducting nystagmus of internuclear ophthalmoplegia
Abducting nystagmus of internuclear ophthalmoplegia (INO) is, as the name implies, nystagmus in the abducting eye contralateral to a medial longitudinal fasciculus (MLF) lesion.
Dependent upon etiology
Onset of spasmus nutans is in infants aged 3-15 months with disappearance by age 3 or 4 years. Rarely, it may be present until children are aged 5-6 years.
A thorough history is important to help determine the etiology of the nystagmus. Important aspects of the history include the following:
A complete neuro-ophthalmic examination is imperative in patients with nystagmus. Aside from a complete ophthalmic examination, including visual acuity, measurement and reactivity of the pupils to light and accommodation, measurement of intraocular pressure, testing the function of extraocular muscles, and anterior and dilated posterior segment examination, other important aspects of the examination include the following:
Nystagmus, Congenital
Ocular flutter
Ocular bobbing
Opsoclonus
Repetitive square wave jerks
Macrosaccadic oscillations
Superior oblique myokymia
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
Use for periodic alternating nystagmus, downbeat and upbeat nystagmus, and seesaw nystagmus.11
Periodic alternating oscillopsia may be a major complaint in patients with periodic alternating nystagmus and may be cured by the use of baclofen.
5 mg PO tid; not to exceed 80 mg qd
<2 years: Not established
2-8 years: 10-40 mg/d PO divided tid/qid
Start: 2.5-5 mg PO tid x 3d; increase by 5-15 mg/d q3d prn; 40 mg/d maximum
8-12 years: 10-60 mg/d PO divided tid/qid
Start: 2.5-5 mg PO tid x 3d; increase by 5-15 mg/d q3d prn; 60 mg/d maximum
>12 years: 20-80 mg/d PO divided tid/qid
Start: 5 mg PO tid x 3d; increase by 5-15 mg/d q3d prn; 80 mg/d maximum
Increased risk of depression with alcohol, antipsychotics, anxiolytics, MAOIs, narcotics, and tricyclic antidepressants; insulin and oral hypoglycemics may increase blood glucose levels
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Caution in renal impairment or patients with seizure disorder
Increases GABA synthesis and release and decreases GABA degradation. Used for acquired pendular nystagmus.
May reduce nystagmus, improve visual acuity, and reduce oscillopsia in patients with acquired pendular nystagmus.
300-1200 mg PO in divided doses
Not established
Antacids may decrease absorption
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Caution in renal impairment and in elderly persons; avoid abrupt withdrawal
Used for downbeat nystagmus. Suppresses muscle contractions by facilitating inhibitory GABA neurotransmission and other inhibitory transmitters.
0.5-5 mg PO tid; not to exceed 20 mg PO qd
<10 years or <30 kg: 0.01-0.03 mg/kg PO divided bid/tid; increase by 0.25-0.5 mg q3d; not to exceed 0.1-0.2 mg/kg/d
>10 years or >30 kg: 0.5 mg PO tid; increase by 0.5-1 mg q3d; not to exceed 20 mg/d
Carbamazepine, phenytoin, and phenobarbital decrease clonazepam levels; cimetidine, itraconazole/ketoconazole, and ritonavir increase clonazepam levels; CNS depressants increase risk of CNS depression; valproic acid increases risk of absence seizures
Documented hypersensitivity
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Caution in patients with impaired respiratory function; avoid abrupt withdrawal
Blocks neuromuscular transmission at cholinergic junctions by preventing release of acetylcholine from nerve terminals. Decreases nystagmus and improves visual acuity.
Treats excessive, abnormal contractions associated with blepharospasm. Binds to receptor sites on motor nerve terminals and inhibits release of acetylcholine, which, in turn, inhibits transmission of impulses in neuromuscular tissue.
Reexamine patients 7-14 d after initial dose to assess for response. Increase doses 2-fold over previous one for patients experiencing incomplete paralysis of target muscle. Do not exceed 25 U when giving it as single injection or 200 U as cumulative dose in 30-day period.
Rectus muscles: 2.5 U/muscle
Retrobulbar injection: 10-25 U in 0.1-1 cm3
Not established
Aminoglycosides or drugs that interfere with neuromuscular transmission may potentiate effects of botulinum toxin
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Systemic side effects have not occurred; however, electrophysiologic studies have shown that large doses produce subclinical effects on neuromuscular transmission in distant muscles
Rucker JC. An update on acquired nystagmus. Semin Ophthalmol. Mar-Apr 2008;23(2):91-7. [Medline].
Sarvananthan N, Surendran M, Roberts E, et al. The prevalence of nystagmus: The Leicestershire nystagmus survey. Invest Ophthalmol Vis Sci. May 20 2009;[Medline].
Wagner JN, Glaser M, Brandt T, Strupp M. Downbeat nystagmus: aetiology and comorbidity in 117 patients. J Neurol Neurosurg Psychiatry. Jun 2008;79(6):672-7. [Medline].
Daroff RB, Troost BT. Upbeat nystagmus. JAMA. Jul 16 1973;225(3):312. [Medline].
Gonzalez C, Seth RK, Ramos-Esteban JC. Change in head posture and character of nystagmus in a patient with neurological upbeat nystagmus. Binocul Vis Strabismus Q. 2007;22(3):179-84. [Medline].
Spielmann AC. Large recession of the four vertical rectus muscles for acquired pendular vertical nystagmus and oscillopsia without a null zone. J AAPOS. Feb 2009;13(1):102-4. [Medline].
Thurtell MJ, Weber KP, Halmagyi GM. Teaching video NeuroImage: acquired or congenital gaze-evoked nystagmus?. Neurology. Jun 3 2008;70(23):e96. [Medline].
Murofushi T, Chihara Y, Ushio M, Iwasaki S. Periodic alternating nystagmus in Meniere's disease: the peripheral type?. Acta Otolaryngol. Jul 2008;128(7):824-7. [Medline].
Menon GJ, Thaller VT. Therapeutic external ophthalmoplegia with bilateral retrobulbar botulinum toxin- an effective treatment for acquired nystagmus with oscillopsia. Eye. Nov 2002;16(6):804-6. [Medline].
Castillo IG, Reinecke RD, Sergott RC, Wizov S. Surgical treatment of trauma-induced periodic alternating nystagmus. Ophthalmology. Jan 2004;111(1):180-3. [Medline].
Kumar A, Thomas S, McLean R, et al. Treatment of acquired periodic alternating nystagmus with memantine: a case report. Clin Neuropharmacol. Mar-Apr 2009;32(2):109-10. [Medline].
American Academy of Ophthalmology. Basic and Clinical Science Course. In: Neuro-ophthalmology. 5. 1999-2000:139-41.
American Academy of Ophthalmology. Basic and Clinical Science Course. In: Pediatric. 69(3). 1999-2000:129-35.
American Medical Association. Drug Evaluations. 1995.
Arnoldi KA, Tychsen L. Prevalence of intracranial lesions in children initially diagnosed with disconjugate nystagmus (spasmus nutans). J Pediatr Ophthalmol Strabismus. Sep-Oct 1995;32(5):296-301. [Medline].
Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol. Jun 1997;41(6):818-25. [Medline].
Baloh RW, Spooner JW. Downbeat nystagmus: a type of central vestibular nystagmus. Neurology. Mar 1981;31(3):304-10. [Medline].
Breen LA. Nystagmus and related ocular oscillations. In: Neuroophthalmology: Clinical Signs and Symptoms. Vol 4. 1997:504-20.
Cross SA, Smith JL, Norton EW. Periodic alternating nystagmus clearing after vitrectomy. J Clin Neuroophthalmol. Mar 1982;2(1):5-11. [Medline].
Donin JF. Acquired monocular nystagmus in children. Can J Ophthalmol. Jul 1967;2(3):212-5. [Medline].
Glaser JS. Neuro-Ophthalmology. 1990.
Leigh RJ, Robinson DA, Zee DS. A hypothetical explanation for periodic alternating nystagmus: instability in the optokinetic-vestibular system. Ann N Y Acad Sci. 1981;374:619-35. [Medline].
Martin JH. Neuroanatomy Atlas. 2nd ed. McGraw-Hill Co; 1996:155-61.
May EF, Truxal AR. Loss of vision alone may result in seesaw nystagmus. J Neuroophthalmol. Jun 1997;17(2):84-5. [Medline].
Neely DE, Sprunger DT. Nystagmus. Curr Opin Ophthalmol. Oct 1999;10(5):320-6. [Medline].
Nolte J. The Human Brain. 1993:218-23.
Norton EW, Cogan DG. Spasmus nutans; a clinical study of twenty cases followed two years or more since onset. AMA Arch Ophthalmol. Sep 1954;52(3):442-6. [Medline].
Pratt-Johnson JA, Tillson G. Management of Strabismus and Amblyopia: A Practical Guide. 1994.
Ruben ST, Lee JP, O'Neil D, Dunlop I, Elston JS. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. Ophthalmology. Apr 1994;101(4):783-7. [Medline].
Sharpe JA, Lo AW, Rabinovitch HE. Control of the saccadic and smooth pursuit systems after cerebral hemidecortication. Brain. Jun 1979;102(2):387-403. [Medline].
Stahl JS, Averbuch-Heller L, Leigh RJ. Acquired nystagmus. Arch Ophthalmol. Apr 2000;118(4):544-9. [Medline].
Troost BT. Nystagmus and Related Ocular Oscillations. Available at: http://www.wfubmc.edu. 1998;[Full Text].
Tusa RJ. Nystagmus: diagnostic and therapeutic strategies. Semin Ophthalmol. Jun 1999;14(2):65-73. [Medline].
Tychsen L. Pediatric Ocular Motility Disorders of Neuro-ophthalmic Significance. Vol. 4. 1991:615-43.
Van Stavern GP, Biousse V, Newman NJ, Leingang JC. Downbeat nystagmus from heat stroke. J Neurol Neurosurg Psychiatry. Sep 2000;69(3):403-4. [Medline]. [Full Text].
acquired nystagmus, downbeat nystagmus, upbeat nystagmus, periodic alternating nystagmus, horizontal nystagmus, vertical nystagmus, optokinetic nystagmus, rotary nystagmus, vestibular nystagmus, oscillopsia, congenital nystagmus, spasmus nutans
Christopher M Bardorf, MD, MS, Ophthalmology, Children's Eye Physicians, Denver, CO
Christopher M Bardorf, MD, MS is a member of the following medical societies: American Medical Association
Disclosure: Nothing to disclose.
Gregory P Van Stavern, MD, FACP, Assistant Professor, Departments of Ophthalmology and Neurology, Wayne State University
Gregory P Van Stavern, MD, FACP is a member of the following medical societies: American Academy of Neurology and North American Neuro-Ophthalmology Society
Disclosure: Nothing to disclose.
Enrique Garcia-Valenzuela, MD, PhD, Clinical Assistant Professor, Department of Ophthalmology, University of Illinois Eye and Ear Infirmary; Consulting Staff, Vitreo-Retinal Surgery, Midwest Retina Consultants, SC, Parkside Center
Enrique Garcia-Valenzuela, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Retina Society, and Society for Neuroscience
Disclosure: Nothing to disclose.
Michael J Bartiss, OD, MD, Medical Director, Ophthalmology, Family Eye Care of the Carolinas
Michael J Bartiss, OD, MD is a member of the following medical societies: American Academy of Ophthalmology, American Academy of Pediatrics, American Association for Pediatric Ophthalmology and Strabismus, and North Carolina Medical Society
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment
Brian R Younge, MD, Professor of Ophthalmology, Mayo Clinic School of Medicine
Brian R Younge, MD is a member of the following medical societies: American Medical Association, American Ophthalmological Society, and North American Neuro-Ophthalmology Society
Disclosure: Nothing to disclose.
Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.
Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.
Related eMedicine topics
Nystagmus, Congenital
Electronystagmography
Dizziness, Vertigo, and Imbalance
Pelizaeus-Merzbacher Disease
Multiple Sclerosis
Clinical guidelines
EFNS task force - therapy of nystagmus and oscillopsia.
Pediatric eye evaluations: I. Screening. II. Comprehensive ophthalmic evaluation.
Eye.
Clinical trials
Visual Impairment, Oscillopsia and Multiple Sclerosis
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)